Adagio Medical Holdings (ADGM) AI Stock Analysis

• Market Cap: $19.46M
• Dividend Yield: N/A
• Average Volume (3M): 35.99K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.20
• Revenue Growth: 2115.38%
• EPS Growth: -4.40%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -20.81
• Shares Outstanding: 15,381,565
• 10 Day Avg. Volume: 13,571
• 30 Day Avg. Volume: 35,995
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: 47.89
• Enterprise Value/Gross Profit: -7.71
• Enterprise Value/Ebitda: -0.16
• 1Y Price Target: $1.00
• Price Target Upside: -20.63% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: $1.00 ▼(-20.63% Downside)

Adagio Medical Holdings faces significant financial challenges, with ongoing losses and negative cash flows being the most impactful factors. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio. While there are positive developments in corporate events, they are not sufficient to offset the financial and technical weaknesses.

Adagio Medical Holdings Business Overview & Revenue Model

Company Description

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.

How the Company Makes Money

Adagio Medical Holdings generates revenue primarily through the sale of its medical devices and diagnostic tools to hospitals, clinics, and healthcare providers. The company implements a direct sales model complemented by distribution partnerships that expand its market reach. Additionally, ADGM may generate income through licensing agreements for its proprietary technologies, as well as through collaborations with research institutions and pharmaceutical companies that seek to integrate its innovations into their therapeutic offerings. These revenue streams are bolstered by ongoing investments in R&D that align with industry trends and regulatory approvals.

Adagio Medical Holdings Financial Statement Overview

Summary

Adagio Medical Holdings is facing significant financial challenges, with consistent losses and negative cash flows. Despite slight improvements in equity and cash position, the company remains highly leveraged and struggles with profitability. The medical devices industry is competitive, and the company needs to address operational inefficiencies and improve revenue generation to achieve financial stability.

Income Statement

Adagio Medical Holdings has experienced declining revenues over the past years, with a negative revenue growth rate from 2023 to 2024. The company has consistently reported negative gross profit and net income, indicating significant challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage, although it has improved from 2023 to 2024 as equity turned positive. The equity ratio remains low, suggesting limited financial stability. Despite improvements in stockholders' equity, the company still faces potential risks due to its high liabilities relative to assets.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, which have slightly improved from 2023 to 2024. The company has relied on financing activities to support its cash position, which may not be sustainable in the long term. The operating cash flow to net income ratio is negative, indicating cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	269.00K	300.00K	189.00K	270.00K
Gross Profit	-1.67M	-1.01M	-686.00K	-888.00K
EBITDA	-62.48M	-27.41M	-23.42M	-19.60M
Net Income	-53.76M	-38.15M	1.07M	-6.56M
Balance Sheet
Total Assets	48.45M	6.83M	151.78M	150.42M
Cash, Cash Equivalents and Short-Term Investments	20.59M	1.38M	91.05K	501.24K
Total Debt	16.27M	39.95M	120.00K	0.00
Total Liabilities	28.54M	48.94M	8.89M	11.22M
Stockholders Equity	19.91M	-42.11M	142.89M	139.20M
Cash Flow
Free Cash Flow	-16.36M	-25.99M	-987.19K	-2.34M
Operating Cash Flow	-15.99M	-25.65M	-485.19K	-19.31M
Investing Cash Flow	-368.00K	-340.00K	-500.00K	-1.27M
Financing Cash Flow	15.63M	21.88M	75.00K	151.07M

Adagio Medical Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.26
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADGM, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.44, below the 50-day MA of 1.38, and below the 200-day MA of 1.43, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 40.86 is Neutral, neither overbought nor oversold. The STOCH value of 41.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADGM.

Adagio Medical Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NMTC	56 Neutral	$41.35M	―	-95.39%	―	135.03%	60.67%
Sector *	51 Neutral	$7.46B	-0.25	-46.00%	2.25%	22.77%	-2.14%
MDAI	45 Neutral	$56.14M	―	256.43%	―	22.27%	49.22%
COCH	40 Neutral	$31.42M	―	1697.39%	―	-26.49%	-91.23%
ADGM	40 Underperform	$19.46M	―	-329.16%	―	2115.38%	-4.40%
MODD	―	$39.98M	―	-131.58%	―	―	―
RBOT	39 Underperform	$44.25M	―	-125.63%	―	―	6.48%

Adagio Medical Holdings Corporate Events

Adagio Medical Reports Q2 Financial Results Progress

On August 13, 2025, Adagio Medical Holdings announced its second quarter financial results, highlighting significant progress in its clinical studies and operational efficiency. The company reported a reduction in cash burn due to prioritization initiatives and continued strong enrollment in the FULCRUM-VT study, which is crucial for its market positioning in the treatment of ventricular tachycardia. Financially, Adagio reduced its net loss compared to the previous year, reflecting improved cost management and strategic focus.